benzoxazoles has been researched along with (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Gal, AA; Khuri, FR; Koo, J; Sun, SY; Yue, P | 1 |
| Mohindra, NA; Platanias, LC | 1 |
| Behtaj, M; Dowlati, A; Fu, P; Kresak, A; Sakre, N; Wildey, G; Yang, M | 1 |
| Chen, M; Chen, ZG; Qian, G; Sun, SY; Wang, D; Wang, LJ; Yao, Y; Zhang, QQ; Zhang, S | 1 |
| Deng, L; Fan, S; Lesinski, GB; Owonikoko, TK; Qian, G; Ramalingam, SS; Sun, SY; Zhang, S; Zheng, H | 1 |
| Bernards, R; Caumanns, JJ; de Jong, S; Jalving, M; Kol, A; Meersma, GJ; van der Zee, AGJ; van Wijngaarden, A; Wisman, GBA | 1 |
| Kirubakaran, S; Shaik, A | 1 |
1 review(s) available for benzoxazoles and (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
| Article | Year |
|---|---|
Evolution of PIKK family kinase inhibitors: A new age cancer therapeutics.
Topics: Benzamides; Benzoxazoles; Humans; Imidazoles; Molecular Targeted Therapy; Morpholines; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Signal Transduction; Triazines | 2020 |
6 other study(ies) available for benzoxazoles and (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
| Article | Year |
|---|---|
Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.
Topics: Animals; Antineoplastic Agents; Benzoxazoles; Cell Line, Tumor; Cyclin D1; F-Box Proteins; Female; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HEK293 Cells; Humans; Indoles; Inhibitory Concentration 50; Maleimides; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Morpholines; Multiprotein Complexes; Naphthyridines; Protein Stability; Proteolysis; Purines; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.
Topics: Benzamides; Benzoxazoles; Biocatalysis; Hematologic Neoplasms; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Triazines | 2015 |
RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Benzoxazoles; Female; Fibroblast Growth Factor 10; Gene Amplification; Humans; Interleukin-7 Receptor alpha Subunit; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Morpholines; Protein Kinase Inhibitors; Pyrimidines; Rapamycin-Insensitive Companion of mTOR Protein; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2017 |
mTORC2 Suppresses GSK3-Dependent Snail Degradation to Positively Regulate Cancer Cell Invasion and Metastasis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Benzoxazoles; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Female; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Transgenic; Morpholines; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Rapamycin-Insensitive Companion of mTOR Protein; Snail Family Transcription Factors; TOR Serine-Threonine Kinases | 2019 |
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation.
Topics: A549 Cells; B7-H1 Antigen; Benzoxazoles; beta-Transducin Repeat-Containing Proteins; Cycloheximide; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; HCT116 Cells; HEK293 Cells; Humans; Leupeptins; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Morpholines; Naphthyridines; Neoplasms; Protein Stability; Pyrimidines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Tumor Cells, Cultured | 2019 |
Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Benzoxazoles; Biomarkers, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Mice, Nude; Morpholines; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |